Eton Pharmaceuticals, Inc. Proceeds from (Repayments of) Debt
Eton Pharmaceuticals, Inc. (ETON) reported Proceeds from (Repayments of) Debt of -$3.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfDebt · last filed 2026-08-13
- 2026-06-30: Proceeds from (Repayments of) Debt 6 month -$3.00M.
- 2025-06-30: Proceeds from (Repayments of) Debt 6 month $0.00.
| Period end | Proceeds from (Repayments of) Debt 6 month |
|---|---|
| 2026-06-30 | -$3.00M 10-Q · filed 2026-08-13 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |